Clinical Trials Directory

Trials / Sponsors / Omeros Corporation

Omeros Corporation

Industry · 25 registered clinical trials3 currently recruiting.

StatusTrialPhaseStarted
RecruitingSafety and Efficacy Study of OMS906 in Patients With C3G and ICGN
C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis
Phase 22024-03-01
RecruitingLong-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria
Phase 22024-02-19
RecruitingEfficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transpla
Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Phase 22023-05-01
CompletedSafety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to R
Paroxysmal Nocturnal Hemoglobinuria
Phase 22023-03-27
UnknownStudy of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria
Phase 12022-12-09
TerminatedSafety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome
Phase 32018-05-02
TerminatedStudy of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
IgA Nephropathy
Phase 32018-04-05
TerminatedSafety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
IgAN, LN, MN
Phase 22016-03-10
CompletedSafety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
Thrombotic Microangiopathies
Phase 22014-11-02
CompletedA Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With o
Unilateral Cataract Extraction, Congenital Cataract
Phase 32014-07-01
TerminatedIntraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery
Intraocular Lens Replacement, Intraoperative Floppy Iris Syndrome
Phase 32014-02-01
TerminatedSafety and Efficacy of OMS643762 in Subjects With Huntington's Disease
Huntington's Disease
Phase 22014-01-01
CompletedSafety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects
Schizophrenia
Phase 22013-09-01
CompletedSafety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phaco
Intraocular Lens Replacement
Phase 32012-04-01
CompletedSafety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
Intraocular Lens Replacement
Phase 32011-09-01
CompletedSafety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopi
Meniscal Tear
Phase 32011-08-01
CompletedSafety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CEL
Cataract
Phase 22010-07-01
CompletedPharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal o
Urinary Calculi, Urinary Stones, Urinary Tract Stones
Phase 1 / Phase 22009-03-01
CompletedExploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsifica
Cataract Extraction
Phase 1 / Phase 22008-05-01
CompletedDouble-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solutio
Postoperative Pain
Phase 2 / Phase 32007-12-01
CompletedPharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urina
Urinary Calculi, Urinary Stones, Urinary Tract Stones
Phase 12007-12-01
CompletedEfficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstructi
Knee Injuries
Phase 32005-06-01
CompletedEfficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) Reconstructi
Knee Injuries
Phase 32004-11-01
CompletedSafety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction
Anterior Cruciate Ligament Reconstruction
Phase 32004-10-01
Approved For MarketingSingle Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab
Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)